

OssDsign - While adding potential, acquisition prompts questions on financing

Redeye raises its long-term estimates and valuation somewhat following OssDsign's broadening towards synthetic bone grafts for spinal fusion through the acquisition of Sirakoss. We have a relatively conservative stance on the new product's sales potential at present, though increased clinical validation and demonstrated commercial interest could prompt a reassessment further out.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[OssDsign - While adding potential, acquisition prompts questions on financing](#)